title: Sustained reduction of MS disability: New player in comparing disease-modifying treatments.
authors.affiliation: From the Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD; and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (M.T.), Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. Bibi.Bielekova@nih.gov.
authors.forename: Bibiana
authors.initials: B
authors.lastname: Bielekova
authors.affiliation: From the Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD; and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (M.T.), Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.
authors.forename: Mar
authors.initials: M
authors.lastname: Tintore
mesh_terms: D006233:Persons with Disabilities; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D007166:Immunosuppressive Agents